Your browser version may not work well with NCBI's Web applications. More information here...
1: Clin Gastroenterol Hepatol. 2007 Aug;5(8):917-20. Epub 2007 Jul 10.Click here to read Links

Fulminant hepatic failure secondary to erlotinib.

Liu W, Makrauer FL, Qamar AA, Jänne PA, Odze RD.

Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. wliu3@bics.bwh.harvard.edu

Erlotinib is a tyrosine kinase inhibitor recently approved by the Food and Drug Administration for the treatment of non-small-cell lung cancer and pancreatic cancer. We report a case of a patient with stage IV non-small-cell lung cancer who died of fulminant hepatic failure as a result of treatment with erlotinib.

PMID: 17625975 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Erlotinib (Tarceva® )

    Erlotinib is used to treat non-small cell lung cancer in patients who have already been treated with at least one other chemotherapy medication and have not gotten better. Erlotinib is also used in combination with anoth...

  • Source: AHFS Consumer Medication Information